A provider toolkit with clinically relevant resources related to diagnosis and management of central precocious puberty.

CPP Provider Toolkit

A pair of experts in the management of diabetes review the role of insulin therapy and review the approval process for biosimilars, including the FDA's approval of the first interchangeable insulin biosimilar.

Interchangeable Insulin Biosimilars: A Game Changer in Diabetes Management

Podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP aimed at providing real-world perspective on the latest advances in diabetes management.

The 2022 meeting of the Association of Diabetes Care and Education Specialists (ADCES) is the first in-person instance of the meeting since 2019. With more than 2500 attendees, the event not only showcased the latest advances in 

 for those in the field, but also provided an opportunity to connect with colleagues that did not exist during the height of the COVID-19 pandemic.

At the 4-day meeting attendees could attend more than 100 individual sessions dedicated to topics ranging from management of CKD to eliminating weight stigma and even suicide prevention issues. Held in Baltimore, MD, the 

 epitomized the unique aspects of the organization, and the profession, that has allowed diabetes care and education specialists to advance the field of diabetes management. While on-site the ADCES’s first in-person meeting in 3 years, 

 caught up with former ADCES diabetes educator of the year Gary Scheiner, MS, CDE, owner and director of Integrated Diabetes Services, to learn more about his reaction to the meeting, its programming, and having an opportunity to collaborate with colleagues.

Endocrinology Network: With this being the first in-person ADCES meeting since 2019, what has your impression been of this year’s meeting?

The in-person aspect is what makes this special for me. I can do a virtual conference, get the information, and I can follow up with questions virtually if I have to, but there is no replacement for the face-to-face interactions, meeting with colleagues, and meeting new people that I get to have here. Also, in the exhibit hall meeting there are opportunities with the various company representatives to learn more about what's new and what's in the pipeline.

Endocrinology Network: What do the themes and topics of discussion at the meeting say about the goals of the ADCES?

Those are valuable areas. I think they are areas that set the diabetes care and education profession apart from others in terms of getting into the trenches and really being able to communicate effectively with patients. I hear so many horror stories about people with all kinds of health conditions who just suffer and don't have good outcomes because of poor communication with their health care providers. If there's one thing a diabetes care and education specialist is good at its communicating. So, it's important because that's sort of our forte.

It's one thing to know something, it's another to communicate effectively, and being able to inspire and motivate others to take good care of themselves. So, I'm proud to be part of that.

Endocrinology Network: How does the diversity of attendees, both in traditional terms and in terms of titles and educational background, improve the ability of the ADCES?

Diversity is so important. It's another kind of trademark of this profession. People from so many different walks of life, whether somebody is from the mental health field, nursing, nutrition, dentistry, exercise, we have certain things in common, but we all have to learn from each other.

A good diabetes care provider has some skills in a lot of different areas. You have to know a little bit about the emotional side of it and be able to address it. You have to understand nutrition, at least to a certain extent. You have to be able to counsel patients on exercise and sports and so on and you also have to understand the medication side. So, having a diverse membership and diverse attendees at a meeting like this, it speaks volumes because we have a chance to learn from each other, collaborate, and expand our skill sets.

Endocrinology Network: As diabetes care and education specialists are tasked with learning more and more, is there any concern they may become overburdened in a similar manner to endocrinologists and primary care providers?

It's an interesting question. I mean, you have a breadth of knowledge and expertise that is forever expanding. I still think it pales in comparison to what an endocrinologist and a primary care physician have to do. It's a fraction, but I think it highlights the need for specialization in diabetes.

The fact that we can focus on just diabetes-related issues, hopefully, we're going to be able to stay on top of that. If you told any physician that you're only going to treat one condition, they could do a great job and they could really hone in on it, but they're asked to treat so many different conditions.

In our case, we're sticking to diabetes. In my case, I work primarily with type 1 diabetes. Those are mainly the areas that I focus on. I know there are other providers who focus almost exclusively on a type 2 diabetes space. So, I think there is some specialization developing even with the certified diabetes care and education specialist community and I'm optimistic that because we're just working in the diabetes space that we'll be able to able to keep up.

Articles

Gary Scheiner, MS, CDE, discusses themes and topics of discussion at ADCES 22.

Themes and Hot Topics at ADCES 22, with Gary Scheiner, MS, CDE

Natalie Bellini, DNP, FNP-BC, is a nurse practitioner specializing in diabetes management with the R&B Medical Group based out of Niagara Falls, NY. 

In many conversations related to diabetes, the focus is solely on patients with type 2 diabetes. Although patients with type 1 diabetes also face an increased risk of adverse outcomes as a result of the condition, they can go overlooked in larger, public health efforts. To combat this and improve care for patients with type 1 diabetes, multiple organizations have been formed with the specific intent of advancing management for this patient population. One of these organizations is the 

With a mission of improving outcomes for the entire T1D population through driving real-world evidence and collaborative change, the organization is regarded as a leader in the space. A nonprofit organization founded in 2009, the Boston-based organization has grown by leaps and bounds in the last 13 years, including becoming a leader in data collection among patients with type 1 diabetes. With a registry including more than 3000 patients with type 1 diabetes, the group partners with major organizations and trialists to help further research as well as patient care.

Association of Diabetes Care and Education Specialists (ADCES) 2022 Annual Meeting

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

 Diana Isaacs, PharmD, and Natalie Bellini, DNP, dive deeper into the T1D Exchange and how they are helping patients in a sit-down interview with David Walton, the chief executive officer of the T1D Exchange. In their conversations, Walton details how he became involved in the organization, how patients can become involved or contribute data, and what plans the organization has for the future.

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives

 is available in an audio-only format on 

In this special edition ADCES 22 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by David Walton, CEO of the T1D Exchange, who takes our hosts on a deep dive into the history of the organization, what it is doing right now to improve patient care, and how it expects to grow and improve management of type 1 diabetes into the future.

Diabetes Dialogue: The T1D Exchange, with David Walton

The Association of Diabetes Care and Education Specialists (ADCES) annual meeting is a showcase, not only of the latest advances in management of diabetes, but also of the passion diabetes care and education specialists bring with them to the frontlines of care. The 

At this year’s meeting, thousands of attendees took to the Baltimore Convention Center and on-demand sessions for updates in diabetes management. Among the attendees to this year’s ADCES annual meeting was Korey Hood, PhD, a staff psychologist and professor at Stanford University. Although not an endocrinologist, Hood is also the founder of 

, an online resource for patients with diabetes. Designed to provide patients with diabetes a one-stop shop for information related to diabetes management, including sections dedicated to finding a CGM device that is best for you, information on new sensors, testimonials on varying topics from other patients with diabetes, and a slew of resources on other topics within diabetes management.

Hood’s goals with DiabetesWise goes beyond just providing information to patients, it has expanded and now includes a site specifically designed for providers of patients with diabetes. This site, 

, is geared towards offering providers with resources to better equip them to manage patients with diabetes, including a device library, a prescription tool, and best practices resources. During his time at ADCES, Hood sat down for an extended conversation with Diana Isaacs, PharmD, and Natalie Bellini, DNP, the hosts of 

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives.

 That conversation with Isaacs and Bellini is the focus of the first of multiple special edition on-site episodes of Diabetes Dialogue recorded at the ADCES 22 annual meeting.

In this special edition of Diabetes Dialogue recorded on-site at ADCES 22, our hosts are joined by Korey Hood, PhD, a staff psychologist and professor at Stanford University. Founder of DiabetesWise and DiabetesWisePro, Hood talks to Diana Isaacs, PharmD, and Natalie Bellini, DNP, about his efforts and how the online resources are pushing care forward.

Diabetes Dialogue: Exploring DiabetesWise, with Korey Hood, PhD

Few fields in medicine have seem the extensive level of collaboration as cardiometabolic health in recent years. As a result of this growing acknowledgement of the intersectionality between metabolic, renal, and cardiovascular conditions, multiple specialties have been tasked with the responsibility of prescribing and optimizing care of 

Although much of this focus was, at least initially, focused on heart failure management in patients with type 2 diabetes. Further examination of SGLT2 inhibitors revealed renoprotective benefits and 

 joined endocrinologists and cardiologists as bearing responsibility for prescribing these agents to patients. More recently, finerenone has demonstrated its ability to reduce the progression of chronic kidney disease in patients with type 2 diabetes and the ongoing FIND-CKD trial will determine whether the nonsteroidal MRA could provide similar benefit in patients without diabetes.

Updates in CKD management in patients with diabetes was the focal point of a session led by Sara Reece, PharmD, director of interprofessional education and associate professor in the School of Pharmacy at the Philadelphia College of Medicine Georgia, at the 

Association of Diabetes Care and Education Specialist (ADCES) 2022 annual meeting

. To learn more about the expectations and updates related to CKD management for members of the diabetes care team, 

reached out to Reece for further insight into the topic. A transcript of that conversation can be found below.

Updates in CKD Management for Patients with Diabetes

Endocrinology Network: Can you describe the main points of emphasis from your presentation on CKD management in type 2 diabetes?

Just thinking in terms of CKD and knowing the role of SGLT2 inhibitors with the ADA Standards of Care for this year clearly stating, for folks with chronic kidney disease and diabetes, that it's appropriate as a first-line treatment to put them on an SGLT2 inhibitor. With folks with chronic kidney disease with and without type two diabetes, finerenone is important for delaying the progression of chronic kidney disease.

Unfortunately, oftentimes, screening is not being done with the GFR and the albuminuria, and it really needs to be done. So, those were the points of emphasis in our presentation. The other is the consideration of making sure folks are getting treatment when they need it and considering, again, right away starting with SGLT2 inhibitors, then also starting finerenone in those with chronic kidney disease to delay the progression.

I think if folks if really did look at some of that trial data, certainly there was enough evidence to justify it to use, especially given the statistics on the number of people that end up with end-stage renal disease that have chronic kidney disease. Although there are folks out there that really wait to look at more evidence. I think of myself, for example, when getting an Apple Watch. I waited a while to get an Apple Watch to let other people try it out. So, I think there's going to be the same type of thing with this particular medication.

Endocrinology Network: What are some areas in immediate need of addressing to improve patient care?

Well, I would say 2 things right off. First, I would say recognizing what I like to call the 3 musketeers: dyslipidemia, hypertension, and diabetes. All of those have to be addressed to really delay progression, or even development of CKD.

So, really addressing all three of those, and making sure that absolutely all three of those being treated appropriately. It's more than just glycemic control. Then the other piece is using time in range, beyond just a HbA1c, because it gives a lot more deeper data and looking at outcomes. That's important when it comes to CKD looking at that time in range.

Endocrinology Network: Is there any concern the growing intersectionality of diabetes and the expanding knowledge base could contribute to burnout among diabetes care and education specialists?

I can absolutely appreciate what you're saying. Working in a family medicine practice with family medicine physicians and between medicine residents, just seeing day in and day out the burden they carry. Burdens of course sounds negative, but just keeping pace of everything because of the umbrella conditions.

It's a little bit different for the Diabetes Care and Education Specialist, I think we're coming to realize as a specialty, diabetes is on a cardiometabolic spectrum. So, as we're keeping up with our knowledge, we've got to think about cardio, vascular, metabolic, and renal in addition to the glycemic aspects of it. So, I think coming to conferences like this are important because you have the opportunities for the sessions to really get that information. After this, when folks go back home to really watch sessions they could not attend and read journals. I know the ADA and the ADCES does a good job with their journals. So, really looking just beyond glycemia but putting in including articles on renal, cardiovascular, and metabolic topics.

Editor's Note: This transcript has been edited for length and clarity. 

After leading a session on the topic at ADCES, Sara Reece, PharmD, sat down to discuss the latest updates in chronic kidney disease management among patients with type 2 diabetes. 

Updates in CKD Management for T2D, with Sara Reece, PharmD

When the words bias and stigma are brought up in medicine, they often refer to disparities related to the racial- or gender-based differences in care for patients. At the 

Association of Diabetes Care and Education Specialists (ADCES) 2022 annual meeting

, a presentation by Scott Kahan, MD, MPH, director of the National Center for Weight and Wellness, took aim at addressing 

 and the impact it can have on patients as well as their ability to meet treatment goals.

According to the National Eating Disorders Association, weight stigma, also known as weight bias or weight-based discrimination, is defined as discrimination or stereotyping based on a person’s weight. With an interest in learning more about the history of weight stigma versus the current landscape and how a new emphasis on patient-first language in diabetes management may influence the fight to eliminate weight stigma in clinical care settings, 

reached out to Kahan, and that conversation is the subject of the following Q&A.

Understanding Weight Stigma, with Scott Kahan, MD, MPH

Endocrinology Network: Can you describe the origins of weight stigma and how it impacts patients today?

So, at the most basic level, weight stigma is driven by assumptions, and often judgments, about people based on their appearance. That goes back forever, because in Western societies and, in particular, in the US, there is just so much judgment about people based on appearance and weight is one of those areas that tends to be judged. Studies on weight stigma started in the mid-20th century, but really increased over the last 20-30 years.

We have been making real progress. Unfortunately, not nearly enough. The progress has largely been made in terms of minimizing explicit weight stigma, like just yelling out at somebody: "You're such a fat slob!". Or something like that. We don't see that nearly as much as we used to, but implicit weight stigma, which is much more subtle. Things where we make assumptions and have various beliefs about people that are, again, driven by their weight. Whether it is about their intelligence or whether about their likelihood to be compliant with medical recommendations. Those are quite common and even ubiquitous. That's something that we haven't made all that much progress on.

Endocrinology Network: How difficult is addressing weight stigma in clinical practice?

It doesn't have to be as difficult as it seems. Ultimately, what we want to communicate to patients is that we care about them and we want to help them to live healthy lives as well as to be able to participate in their lives and not be limited. Whether by their weight and weight problems, like diabetes, and, certainly, not to be limited by experiencing weight stigma, the important thing to get across to patients is to communicate that gaining a lot of weight is not a healthy thing, to communicate those healthful behaviors will improve their lives, their enjoyment of their lives, and their quality of life. Typically, this is done without words—it's done in the tone of our voice and it's done in the way we interact with them. But let them know that carrying excess weight doesn't make them a bad person, nor does losing weight make them a good person. We want to separate the condition and the behaviors from the value of the person itself.

Endocrinology Network: How does use of patient-first language in diabetes and obesity management help reduce weight stigma?

So, I certainly think there's a lot of overlap. In some ways, the use of patient-first language in obesity is following on the heels of the use of patient-first language in diabetes. The focus on that started earlier in the field of diabetes. It didn't start with diabetes, there's plenty of other areas that we were it's now second nature to us people first language.

For example, we don't call people with depression, depressives. It's just it's not natural and, largely, I think in diabetes we've made a lot of progress. It's not common anymore to call people with diabetes, diabetics. We're quite at the early stages of imparting the importance of using people-first language in obesity. So, we'll see where that goes.

I think it's a very important thing, in part, because it's a really easy thing. There are a lot of things that take time and money and effort. This is not one of them. It takes just a little bit of attention and a little bit of practice. It's nothing off our shoulders to utilize people first language and it makes a difference. No one likes to be called obese, let alone morbidly. So, there are plenty of studies showing that the terminologies we use can be more or less motivating for patients. It's a subtle thing, but it's an important thing and a valuable thing for all clinicians to consider when they interact with their patients.

Editor's note: This transcript has been edited for length and clarity.

Scott Kahan, MD, MPH, discusses the concept of weight stigma, its historical impact, and avenues for confronting weight stigma that currently exists in clinical care settings. 

Confronting Weight Stigma in Obesity Care, with Scott Kahan, MD, MPH

Results of a randomized trial comparing the use of lower and higher glycemic criteria groups to diagnose 

Named the GEMS trial, results of the study indicate use of the lower glycemic threshold led to more diagnoses of gestational diabetes, which led to greater use of healthcare services, but was not associated with a lower risk of adverse events or delivering a large-for-gestational-age infant.

“Use of the lower glycemic criteria, as expected, led to a higher percentage of women receiving a diagnosis of gestational diabetes than use of the higher glycemic criteria; therefore, use of health services, which included induction of labor, care for diabetes, pharmacotherapy for blood glucose control, and treatment for neonatal hypoglycemia, was greater in the lower-glycemic-criteria group,” wrote investigators. “Overall, the risks of giving birth to a large-for-gestational age infant and of other infant or maternal complications were not lower with the lower glycemic criteria than with the higher glycemic criteria.”

Led by a team of investigators from New Zealand, the Gestational Diabetes Mellitus Trial of Diagnostic Detection Thresholds (GEMS) randomized women with a singleton pregnancy receiving antenatal care who had a 75-gram oral glucose-tolerance test (OGTT) for gestational diabetes at 24-32 weeks to be evaluated using a lower or higher glycemic criteria for diagnosis of gestational diabetes. With financial support from the Health Research Council of New Zealand and other New Zealand-based institutions, the trial’s primary outcome was the birth of an infant who was large for gestational age, which was denied as a birth weight above the 90th percentile according to Fen-World Health Organization standards. The trial’s secondary outcomes of interest included multiple maternal and infant health outcomes, including induction of labor, use of health services, use of pharmacologic agents, and risk of adverse events.

For the purpose of analysis, the lower glycemic criterion was a fasting plasma glucose level of at least 92 mg/dL(≥5.1 mmol/L), a 1-hour level of at least 180 mg/dL (≥10.0 mmol/L), or a 2-hour level of at least 153 mg/dL (≥8.5 mmol/L) and the higher glycemic criterion was a fasting plasma glucose level of at least 99 mg/dL (≥5.5 mmol/L) or a 2-hour level of at least 162 mg per deciliter (≥9.0 mmol/L).

With recruitment beginning in April 2015 and lasting through August 2020, investors screened 5662 women for eligibility and 4061 underwent randomizations into the trial. After randomization, 2022 were assigned to the lower glycemic criteria and 2039 were assigned to the higher glycemic criteria. Of the 4061 who underwent randomization, 4050 women and their infants completed follow-up to the time of hospital discharge after birth. No significant differences were observed for the characteristics of women included in each arm of the trial.

Overall, 15.3% in the lower glycemic criteria group and 6.1% in the higher glycemic criteria group received a diagnosis of gestational diabetes. Of the 2019 offspring born to women in the lower glycemic criteria group, 8.8% were large for gestational age compared to 8.9% of the 2031 infants born to women in the higher glycemic criteria group (aRR, 0.98 [95% CI, 0.80-1.19]; 

=.82). Further analysis demonstrated induction of labor, use of health services, use of pharmacologic agents, and neonatal hypoglycemia occurred more commonly in the lower glycemic criteria group than among the higher glycemic group.

In a subgroup of women who had OGTT results fall between the lower and higher glycemic criteria, those treated for gestational diabetes experienced improved maternal and infant health benefits, including fewer large-for-gestational-age infant, compared with those who were not treated for gestational diabetes. Among the additional findings highlighted by investigators was an increase in infants with hypoglycemia warranting treatment in the lower glycemic criteria group, which investigators suggested was likely due to the higher percentage of infants born to a mother with a diagnosis of gestational diabetes that were identified as requiring additional screening.

, Michael Greene, MD, of Department of Obstetrics and Gynecology, Harvard Medical School, summarized the results of the study and reflected on the additional research needed to identify the optimal approach to diagnosing gestational diabetes with the aim of improving outcomes for mother and child.

“Ultimately, diagnosing gestational diabetes in more women through the use of the lower glycemic criteria in this trial neither improved nor worsened outcomes for the mothers or their babies. The perfect line for diagnosing gestational diabetes has yet to be drawn,” Greene wrote.

Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes

Despite increasing the rate of diagnoses and healthcare utilization, the GEMS study found a lower glycemic criterion for diagnosis of gestational diabetes was not associated with a reduced risk of negative outcomes for mother and offspring.

No Difference in Outcomes with Lower Glycemic Threshold for Diagnosing Gestational Diabetes

The Gerontological Society of America has released a new toolkit aimed at providing primary care clinicians with guidance that will aid in improving the recognition and care for older 

Released on August 16, the toolkit was created to outline optimal strategies for obesity management in this patient population through a specific framework, named the “KAER” framework, designed to break down implementation of best practices in 4 specific categories for primary care clinicians.

“Primary care physicians and providers are often challenged when they care for patients with obesity. This concern for competence is a derivative of inadequate training in obesity,” said Fatima Cody Stanford, MD, MPH, an associate professor of medicine and pediatrics at Harvard Medical School and an obesity medicine physician-scientist at Massachusetts General Hospital, 

. “This toolkit serves as a reference for any clinician who seeks to provide patient-centered care for this patient population.”

A 63-page document published on the Gerontological Society of America website and developed with support from Novo Nordisk, the toolkit is broken down into 4 unique sections titled: Kickstart, Assess, Evaluate, and Refer (KAER). Using this KAER framework, each of the 4 sections within the toolkit contain subsections on key takeaways, an overview, and optimal approaches to implementation. In the aforementioned statement, the Gerontological Society of America outlined the specific goals of the KAER framework.

 the weight management conversation in the primary care setting with a focus on obesity as a disease, not a behavioral issue or problem based on poor choices.

 for overweight and obesity, underlying conditions, contributing medications, and overall health.

treatment options based on assessment, discuss with patient, implement, and monitor outcomes.

for community resources to assist on the weight management journey.

With more than 2 dozen references, the document also provides additional resources regarding weight loss and obesity management from other organizations, including the Academy of Nutrition and Dietetics, the American Academy of Physician Associates, and the American Association of Clinical Endocrinology, among others.

“We are grateful to our peer review panel who informed the development of the KAER Toolkit,” said Karen Tracy, vice president, strategic alliances and integrated communications at the Gerontological Society of America. “Their expertise allowed us to infuse the toolkit with the best available tools and resources for primary care teams to use while providing care to older adults with overweight and obesity. The toolkit includes important information that supports primary care teams to identify and address their own biases and practices that impede person-centered, sensitive care for individuals with overweight and obesity — an important first step in implementing the KAER Framework to support older adults with these chronic and complex conditions.”

The Gerontological Society of America Toolkit for the Management of Obesity in Older Adults

Gerontological Society of America website.

On August 16, the Gerontological Society of America released a 63-page provider toolkit aimed at providing clinicians managing older patients with obesity with necessary tools and resources to improve the recognition and treatment of obesity in this patient population.

GSA Releases New Toolkit for Obesity Management in Older Adults

 was a showcase of the latest clinically applicable advances in diabetes management. With more than 2500 attendees, the meeting’s focus ranged from diabetes technology to therapeutics and even clinical process. Among the more than 100 sessions occurring across the 4-day conference, were a trio of sessions led by Jennifer Clements, PharmD, clinical professor and director of pharmacy education at the University of South Carolina College of Pharmacy.

During her time at the meeting, Clements was the primary presenter for a trio of sessions focus on U-500 insulin in the inpatient setting, treatment and prevention strategies for hypoglycemia, and clinical implications for SGLT2 inhibitors in chronic kidney disease for patients with diabetes. Clements also participated in other roles, either as a co-presenter or moderator, on a pair of sessions related to mental health support and using virtual reality to educate about psychosocial issues in diabetes.

which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with Clements following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management.

In this edition of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management.

Diabetes Dialogue: Updates in Diabetes Management at ADCES, with Jennifer Clements, PharmD

 has become a focal point for diabetes care and education specialists: use of new technologies to improve care. With many in patient-facing roles, optimal uptake and dissemination of information, and the technologies themselves, have led to diabetes technology becoming a main topic of discussion at the Association of Diabetes Care and Education Specialists (ADCES) annual meeting and for good reason. In just the first half of 2022, major regulatory decisions have been made related to Omnipod 5, Eversense E3, and the FreeStylen Libre 3 devices. 

With an interest in learning more about the real-world need for diabetes care and education specialists in advancing use of 

 sat down Gary Scheiner, MS, CDE, owner and clinical director of Integrated Diabetes Services, at the 

 for his perspective on the ever-changing landscape. That conversation is the subject of the video found below:

Gary Scheiner, MS, CDE, discusses updates in diabetes technologies from the ADCES annual meeting, the role of CDES in optimizing uptake and use of new technology, and the ADCES's push to advance diabetes management. 

The Role of Diabetes Care and Education Specialists on Leveraging Technology in Diabetes, with Gary Scheiner, MS, CDE

Among the most coveted honors among those in the diabetes community is the Association of Diabetes Care and Education Specialists (ADCES) award for the diabetes care and education specialist of the year. An award granted to recipients as an honor for special contortions to the field of diabetes management through dedication, innovation, and sensitivity to patient care, the 2022 awardee is Anastasia Albanese-O’Neill, PhD, director of community screening and clinical trials education at the Juvenile Diabetes Research Foundation (JDRF).

An individual who found unexpectedly found her way to the diabetes community as a result of personal connection, O’Neill joined the field later than many of her colleagues, but her time in the field has been characterized by her fervor to advance care of patients with type 1 diabetes. Ahead of the 

 Diana Isaacs, PharmD, and Natalie Bellini, DNP, reached out to O’Neill to take part in an interview about what inspires her passion, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

That conversation is the subject of the special edition ADCES 22 episode of Diabetes Dialogue found below: